Siponimod

Evidence-based neurology checklist on siponimod: Pharmacology Siponimod is a sphingosine-1-phosphate receptor modulator It acts on SIP1 and SIP5 receptors Indications Dose Benefits Complications Acronym

Pharmacology

  • Siponimod is a sphingosine-1-phosphate receptor modulator
  • It acts on SIP1 and SIP5 receptors

Indications

Dose

Benefits

Complications

Acronym

References

  1. Chaudhry BZ, Cohen JA, Conway DS. Sphingosine 1-phosphate receptor modulators for the treatment of multiple sclerosis. Neurotherapeutics 2017; 14:859-873.
  2. Subei AM, Cohen JA. Sphingosine 1-phosphate receptor modulators in multiple sclerosis. CNS Drugs 2015; 29:565-575. 
  3. Kappos L, Li DK, Stüve O, et al. Safety and efficacy of siponimod (BAF312) in patients with relapsing-remitting multiple sclerosis: dose-blinded, randomized extension of the phase 2 BOLD study. JAMA Neurol 2016; 73:1089-1098. 
  4. Kappos L, Bar-Or A, Cree BAC, et al; EXPAND Clinical Investigators. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet 2018; 391:1263-1273.
  5. O'Sullivan C, Schubart A, Mir AK, Dev KK. The dual S1PR1/S1PR5 drug BAF312 (Siponimod) attenuates demyelination in organotypic slice cultures. J Neuroinflammation 2016; 13:31.
  6. And 6 more. Subscribe to see the full list

Related checklists

Loading...